Ocugen, Inc.
OCGN$643M
Small CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaMALVERN
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Sep 28, 2026
28wMarket Overview
Stock performance and key metrics
OCGN News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Brimonidine Tartrate
Dry Eye
OCU410ST
Stargardt Disease
OCU400 Low Dose
Retinitis Pigmentosa
Brimonidine
Dry Eye
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Brimonidine Tartrate | Phase 3 | Dry Eye | - | - |
OCU410ST | Phase 3 | Stargardt Disease | - | - |
OCU400 Low Dose | Phase 2 | Retinitis Pigmentosa | - | - |
Brimonidine | Phase 2 | Dry Eye | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply